The QualityStocks Daily Thursday, April 7th, 2022

Today's Top 3 Investment Newsletters

QualityStocks(MDVL) $1.4100 +64.43%

MarketClub Analysis(SBFM) $9.6500 +53.42%

MiningNewsWire(UEC) $5.5200 +14.76%

The QualityStocks Daily Stock List

Solid Biosciences (SLDB)

MarketBeat, MarketClub Analysis, Schaeffer's, BUYINS.NET, StockMarketWatch, InvestorPlace, QualityStocks, StreetInsider, Trades Of The Day, TradersPro, Zacks, Market Intelligence Center Alert, InvestorsUnderground, InvestorsObserver Team, Technology Profits Daily, Investopedia, Daily Trade Alert and Kiplinger Today reported earlier on Solid Biosciences (SLDB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Solid Biosciences Inc. (NASDAQ: SLDB) is a biotechnology firm that is focused on the development of devices and therapies for DMD, or duchenne muscular dystrophy, in the U.S. The ailment is a genetic muscle-wasting condition that primarily affects boys. Most patients usually display symptoms between ages 3 and 5.

The firm is based in Cambridge, Massachusetts and was incorporated in March 2013 by Gilad David Hayeem, Annie Ganot, Matthew Bennett Arnold, Andrey J. Zarur and Ilan Ganot. It serves consumers in the United States.

The enterprise’s goal is to improve the quality of life of patients with DMD. It is party to a strategic collaboration with Ultragenyx, which entails the development and commercialization of novel gene therapies for DMD. It has classified its programs into assistive devices, ailment-modifying therapies and corrective therapies.

The company’s product pipeline includes a gene transfer candidate dubbed SGT-001, which is currently undergoing phase1/2 clinical trial testing its efficacy in restoring functional dystrophin protein expression in patients. It is also developing a disease modifying program dubbed Anti-LTBP4, indicated for the reduction of inflammation of fibrosis, which helps stabilize the LTBP4 protein. The firm also develops sensors and biomarkers while its Solid Suit program develops wearable assistive devices that offer both therapeutic and functional benefits.

The firm recently provided an update on their IGNITE DMD clinical trial, with its CEO noting that they had progressed with dosing patients and would monitor patient outcomes, adding that they expected good results given the durability of the microdystrophin protein observed in the patients. This, he said, could potentially have a huge impact on the patients’ lives, as it could improve their quality of life. If all goes well, the firm will be helping to meet a previously unmet need, which will benefit many other patients who suffer from this ailment while also bringing in more investments.

Solid Biosciences (SLDB), closed Thursday's trading session at $1.21, up 9.009%, on 718,543 volume. The average volume for the last 3 months is 717,305 and the stock's 52-week low/high is $0.721/$5.79.

Cumberland Pharmaceuticals (CPIX)

MarketClub Analysis, QualityStocks, MarketBeat, Zacks, SmarTrend Newsletters, PennyOmega, CRWEWallStreet, BestOtc, CRWEFinance, CRWEPicks, DrStockPick, Marketbeat.com, PennyToBuck, StreetInsider, TradersPro, StockHotTips, StockMarketWatch, StockOodles, SmallCapVoice, TraderPower, Barchart, BUYINS.NET, Tiny Gems, Momentum Traders, Street Insider, Market FN, AnotherWinningTrade, Stock Research Newsletter and Daily Markets reported earlier on Cumberland Pharmaceuticals (CPIX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) (FRA: CBJ) is a specialty pharmaceutical firm that is engaged in acquiring, developing and commercializing branded prescription products for rheumatology, gastroenterology and hospital acute care in the U.S. to address poorly met or unmet medical needs.

The firm has its headquarters in Nashville, Tennessee and was founded in 1999. It operates in the healthcare sector, under the biotech and pharma sub-industry. Cumberland Pharmaceuticals sells and markets its products through district managers and sales representatives.

The enterprise’s product pipeline is made up of a formulation that was developed for the treatment of duchenne muscular dystrophy, systemic sclerosis and aspirin-exacerbated respiratory disease dubbed ifetroban, which is currently undergoing a phase 2 clinical trial. The formulation recently concluded phase 2 clinical trials evaluating its effectiveness in treating portal hypertension and hepatorenal syndrome. In addition to this, the enterprise is also involved in the development of the RediTrex injection, indicated for disabling psoriasis and treating severe psoriatic and juvenile idiopathic arthritis as well as active rheumatoid arthritis; the Vibative injection indicated for the treatment of various severe bacterial infections and the Vaprisol injection indicated for the treatment of hypervolemic and euvolemic hyponatremia. Furthermore, it also develops Omeclamox-Pak for treating duodenal ulcer disease and Helicobacter pylori infection; a prescription laxative dubbed Kristalose developed to treat acute and chronic constipation; an injection known as Caldolor for treating fever and pain; and an injection termed Acetadote, which is indicated for treating acetaminophen poisoning.

The company’s Vibativ injection has been found to be effective in the treatment of secondary bacterial infections in coronavirus patients, as per patient case studies that were recently released. This formulation, when brought to the market, will cater to a poorly met need and extend the firm’s consumer reach, which will in turn bring in more investors.

Cumberland Pharmaceuticals (CPIX), closed Thursday's trading session at $3.03, up 9.3863%, on 109,157 volume. The average volume for the last 3 months is 108,557 and the stock's 52-week low/high is $2.20/$7.51.

Medavail Holdings (MDVL)

QualityStocks, MarketBeat, Greenbackers, The Street, InvestorPlace, Schaeffer's, The Growth Stock Wire, TradersPro, MarketBeat, Hit and Run Candle Sticks, TopStockAnalysts, Energy and Capital, HotStockProfits, Stock Gumshoe, Wall Street Resources, Daily Trade Alert, Penny Detectives, Daily Markets, Bull Warrior Stocks, Money Morning, Zacks, Inside Investing Daily, OTCPicks, Growth Stock Wire, Investing Daily, FeedBlitz, ChartAdvisor, StreetInsider, Wealth Daily, Uncommon Wisdom, Trading Tips, Trades Of The Day, Tiny Gems, The Trading Report, The Stock Analyzer, QualityStocks, Taipan Daily, Penny Stock, StreetAuthority Daily, Stocks That Move, StockMarketWatch, SpeculatingStocks, SmallCap Fortunes, PennyTrader Publisher, PennyPro and The Bull Report reported earlier on Medavail Holdings (MDVL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Medavail Holdings Inc. (NASDAQ: MDVL) (FRA: 73M0) is a tech-enabled pharmacy firm that is engaged in the provision of pharmacy services.

The firm has its headquarters in Mississauga, Canada and was incorporated in 2007, on April 11th. It serves consumers in Canada.

The company operates through the pharmacy technology segment and the retail pharmacy services segment. It sells and licenses its proprietary software and hardware to retailers, health systems and other industry consumers who would like to leverage their own pharmacy operations to bring greater service, automation and convenience to their members and patients. The company also assists patients in optimizing drug adherence, leading to better health outcomes.

The enterprise is involved in the development and commercialization of a pharmacy, kiosk, mobile application and drive-thru solution. Its primary technology and product is a prescription dispensing system which is customer-interactive and controlled by the pharmacist, dubbed MedCenter. This technology is akin to a prescription-dispensing ATM or a pharmacy in a box. The MedCenter enables live pharmacist counselling through 2-way audio-video communication. The enterprise also operates a full-service retail pharmacy known as SpotRx, which uses its automated pharmacy technology. In addition to this, it develops and commercializes advanced nutrition products that boost muscle health and performance.

The firm recently entered into a strategic arrangement with Zipdrug, which selected SpotRx as its primary partner. The move will allow SpotRx to serve consumers in the Tucson area, which will not only extend the firm’s consumer reach but also afford it more expansion opportunities. This may in turn boost the firm’s growth.

Medavail Holdings (MDVL), closed Thursday's trading session at $1.41, up 64.4315%, on 80,097,196 volume. The average volume for the last 3 months is 71.836M and the stock's 52-week low/high is $0.785801/$14.59.

Denison Mines (DNN)

Streetwise Reports, AllPennyStocks, Greenbackers, The Street, InvestorPlace, Schaeffer's, The Growth Stock Wire, TradersPro, MarketBeat, Hit and Run Candle Sticks, TopStockAnalysts, Energy and Capital, HotStockProfits, Stock Gumshoe, Wall Street Resources, Daily Trade Alert, Penny Detectives, Daily Markets, Bull Warrior Stocks, Money Morning, Zacks, Inside Investing Daily, OTCPicks, Growth Stock Wire, Investing Daily, FeedBlitz, ChartAdvisor, StreetInsider, Wealth Daily, Uncommon Wisdom, Trading Tips, Trades Of The Day, Tiny Gems, The Trading Report, The Stock Analyzer, QualityStocks, Taipan Daily, Penny Stock, StreetAuthority Daily, Stocks That Move, StockMarketWatch, SpeculatingStocks, SmallCap Fortunes, PennyTrader Publisher, PennyPro and The Bull Report reported earlier on Denison Mines (DNN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Denison Mines Corp. (NYSE American: DNN) (TSE: DML) (FRA: IUQ) is a uranium exploration and development firm which is focused on acquiring, exploring for and developing uranium properties, as well as processing and selling uranium.

The firm has its headquarters in Toronto, Canada and was incorporated in 1997, on May 9th. Prior to its name change in December 2006, the firm was known as International Uranium Corp. It operates as part of the mining industry and serves consumers in Canada.

The company operates through the corporate and other, environmental services and mining segments. The corporate segment is involved in the provision of general management and administrative services to UPC (Uranium Participation Corporation) while the environmental segment is involved in the operations of the company’s environmental services business, through Denison Environmental Services. UPC invests in uranium hexafluoride and uranium oxide. On the other hand, the mining segment includes activities related to the exploration, evaluation and development, mining, milling and selling of mineral concentrates.

The enterprise holds interests in various exploration and evaluation projects in Canada. Its portfolio comprises of projects covering over 300,000 hectares. The enterprise’s primary project is the Wheeler River uranium project in which it holds a 95% interest. The project is situated in the north Saskatchewan Athabasca Basin region. In addition to this, the enterprise explores for uranium in Zambia and Mongolia.

The company is currently developing the high-grade uranium Phoenix deposit. This move makes them well-positioned to compete with current uranium producers in the near future when the market requires additional sources of production. This is good news not only for the company’s shareholders, but also for its growth.

Denison Mines (DNN), closed Thursday's trading session at $1.79, up 11.1801%, on 24,609,099 volume. The average volume for the last 3 months is 24.395M and the stock's 52-week low/high is $0.9155/$2.14.

Momentus Inc. (MNTS)

QualityStocks, MarketClub Analysis and MarketBeat reported earlier on Momentus Inc. (MNTS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Momentus Inc. (NASDAQ: MNTS) is a space infrastructure firm that is engaged in the provision of in-space transportation services.

The firm has its headquarters in San Jose, California. Prior to its name change, the firm was known as Stable Road Acquisition Corp. It serves consumers around the globe.

The company focuses on space transportation, in-orbit servicing and satellite as a service, which are three important functions in the new space economy. Its objective is to provide infrastructure services to support the burgeoning space economy. The company plans to help customers optimize the destination of space, with in-space transportation as its core service.

The enterprise builds service and transfer vehicles that ferry hosted payloads and satellites between orbits in space. It also provides other infrastructure services, which include satellite inspection and dead satellite removal, among other service offerings. Its service and transport vehicles comprise of Fervoride, Ardoride and Vigoride. Fervoride has been designed to move cargo across more than one space destination, while Ardoride is designed to deliver medium-sized and small satellites to custom orbits like Moon Orbit, Highly Elliptical Orbit, Geosynchronous Orbit or Medium Earth Orbit. On the other hand, Vigoride launches mid to small-sized rockets as well as adjusts inclination, changes orbital planes and delivers to Low Earth Orbit altitudes. The enterprise serves launch providers, satellite manufacturers, defense primes, satellite operators and government agencies.

The company is preparing to launch its first Vigoride vehicles by June 2022, after it received the appropriate government licenses to support the mission. This move will not only allow the company to test their technology’s effectiveness in space but also catapult the company into the market, which will be good for investments as well as its growth.

Momentus Inc. (MNTS), closed Thursday's trading session at $4.39, up 48.8136%, on 193,312,029 volume. The average volume for the last 3 months is 193.312M and the stock's 52-week low/high is $1.85/$14.69.

LianBio (LIAN)

QualityStocks and MarketBeat reported earlier on LianBio (LIAN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

LianBio (NASDAQ: LIAN) is a biopharmaceutical firm that is focused on the development and commercialization of medications for the treatment of inflammatory, cardiovascular, ophthalmology, respiratory and oncology ailments.

The firm has its headquarters in Princeton, New Jersey and was incorporated in 2019. The firm serves consumers around the globe, with a focus on the United States, China and other Asian countries.

The company is party to a partnership with Nanobiotix S.A., which entails the development and commercialization for a radiosensitizer dubbed NBTXR3, which is designed to be injected into a malignant tumor before standard radiotherapy. It is also party to a partnership with Tarsus Pharmaceuticals Inc., which involves the development and commercialization of an eye solution known as TP-03, to treat Demodex blepharitis.

The enterprise’s product portfolio is made up of NH-13 for the treatment of ulcerative colitis; a formulation known as BBP-398 for the treatment of solid tumors; LYR-210 for chronic rhinosinusitis; a formulation known as infigratinib for first-line and second-line cholangio carcinoma; a formulation dubbed sisunatovir for the treatment of respiratory syncytical virus; and Omilancor for Crohn’s disease. It is also involved in the development of mavacamten, to treat heart failure with preserves ejection fraction, and non-obstructive and obstructive hypertrophic cardiomyopathy.

The firm’s Infrigratinib formulation recently received approval from the Hainan Province’s Health Commission and Medical Products Administration, for the treatment of metastatic cholangio carcinoma. This move brings the firm one step closer to addressing unmet patient needs, which will benefit the patients and have a positive influence on its growth.

LianBio (LIAN), closed Thursday's trading session at $5.4, up 9.0909%, on 992,586 volume. The average volume for the last 3 months is 992,586 and the stock's 52-week low/high is $2.605/$16.37.

Conduent Inc. (CNDT)

MarketClub Analysis, MarketBeat, StocksEarning, StreetInsider, Daily Trade Alert, InvestorPlace, The Street, QualityStocks, Marketbeat.com, Daily Profit, BUYINS.NET, StockMarketWatch, Zacks, The Online Investor, The Wealth Report, Trades Of The Day, Trading Tips and Schaeffer's reported earlier on Conduent Inc. (CNDT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Conduent Inc. (NASDAQ: CNDT) (FRA: 4C0) is a business process services firm that is engaged in the provision of business process services with capabilities in transaction-intensive automation, analytics and processing.

The firm has its headquarters in Florham Park, New Jersey and was incorporated in 2016. The firm serves consumers around the globe, with a focus on Europe and the United States.

The enterprise operates through the Transportation, Government services and Commercial industries segments. The commercial segment provides customized solutions and business process services to clients in a number of industries, including healthcare and human resource services, transaction processing services, end-user customer experience management services and learning services. The transportation segment provides system and support services comprising of mission-critical payment and mobility solutions to government clients. This segment also offers mileage-based user, urban congestion management and electronic tolling solutions; parking enforcement, curbside demand management, citation and permit administration solutions; transit solutions; and automatic vehicle/ computer-aided dispatch solutions. On the other hand, the government services segment offers government-centric business process services to the local, state and federal U.S. governments, as well as foreign governments, for transaction processing, program administration, payment and public assistance services; child support, payment solutions, government healthcare and federal services; fiscal agent care management and medical management services.

The company recently finalized the sale of its Midas Suite of Solutions to Symplr. It plans to use its net proceeds to invest in its business while focusing on synergies within its portfolio which will enhance client and shareholder value. This will have a positive impact on its growth and help bring in more investors into the company.

Conduent Inc. (CNDT), closed Thursday's trading session at $5.38, up 10.6996%, on 6,619,731 volume. The average volume for the last 3 months is 6.62M and the stock's 52-week low/high is $4.12/$8.50.

Decibel Therapeutics (DBTX)

MarketBeat reported earlier on Decibel Therapeutics (DBTX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Decibel Therapeutics Inc. (NASDAQ: DBTX) is a clinical-stage biotechnology firm that is focused on the discovery and development of transformative therapies for balance and hearing disorders.

The firm has its headquarters in Boston, Massachusetts and was incorporated in October 2015 by Albert Edge, Ulrich Müller, Gabriel Corfas, M. Charles Liberman and Kevin Paul Starr. Prior to its name change in April 2014, the firm was known as Hearing Inc. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm has two companies in its corporate family and serves consumers in the U.S.

The company is party to a strategic collaboration with Regenron Pharmaceuticals Inc. entailing the development of gene therapies for various forms of congenital hearing loss.

The enterprise’s product pipeline is made up of AAV.104 to restore hearing in patients with stereocilin deficiency; AAV.103 to restore hearing in patients with gap junction beta-2 deficiency; and DB-020, to prevent hearing loss induced by cisplatin. It also develops gene therapy programs, AAV.201 and DB-ATO, to restore balance in individuals suffering from bilateral vestibulopathy through the regeneration of lost hair cells in the vestibule. The enterprise also develops DB-OTO, to offer hearing to patients born with profound hearing loss caused by the otoferlin gene’s mutation.

The firm recently announced its latest financial results, with its CEO noting that they remained focused on bringing its transformative therapies to patients suffering hearing and balance disorders. The success and approval of these treatments will not only benefit patients with these indications but also bring in significant revenue into the firm.

Decibel Therapeutics (DBTX), closed Thursday's trading session at $2.42, off by 5.098%, on 49,545 volume. The average volume for the last 3 months is 48,914 and the stock's 52-week low/high is $2.40/$11.62.

Curis Inc. (CRIS)

Wall Street Resources, Greenbackers, MarketBeat, StreetInsider, MarketClub Analysis, Contrarian Press, QualityStocks, The Street, StockMarketWatch, Today's Financial News, TradersPro, Investors Alley, TraderPower, SmallCapVoice, Zacks, StockOodles, SmarTrend Newsletters, OTCtipReporter, Stock Rocket Report, Hit and Run Candle Sticks, Street Insider, Marketbeat.com, Daily Profit, PennyStockScholar, Bull Warrior Stocks, TopPennyStockMovers, BUYINS.NET, Market FN, Jason Bond, Contrarian Wealth Coalition, Daily Markets, INO.com Market Report, FeedBlitz, HotOTC, CRWEFinance, CRWEWallStreet, Investment House, Stock Analyzer, Wealth Daily, The Online Investor, The Best Newsletters, StreetAuthority Daily, StockHotTips, StockEgg, Stock Shock and Awe, PennyStockDD, Stock News Now, MarketWatch, Schaeffer's, PennyTrader Publisher, PennyToBuck, AtomicPennyStocks, PennyPro, Penny Invest, MicrocapVoice and Stock Rich reported earlier on Curis Inc. (CRIS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Curis Inc. (NASDAQ: CRIS) is a biotechnology firm that is focused on discovering and developing drug candidates for treating human cancers.

The firm has its headquarters in Lexington, Massachusetts and was incorporated in 2000, on February 14th. It operates as part of the biotechnology industry, under the healthcare sector. The firm mainly serves consumers in the United States.

The company is party to a collaboration agreement with Aurigene Discovery Technologies Ltd, which involves discovering, developing and commercializing small molecule compounds in the areas of precision oncology and immuno-oncology. It is also party to a collaboration agreement with Genentech Inc. And F. Hoffmann-La Roche Ltd, which entails developing and commercializing an orally administered small molecule signaling pathway inhibitor known as Erivedge, to treat advanced basal cell carcinoma.

The enterprise’s candidates include a small molecule drug candidate dubbed CA-170, for the treatment of lymphomas and advanced solid tumors; a monoclonal antibody known as CI-8993, which has been developed to antagonize the V-domain Ig suppressor of T cell activation; and an oral small molecule drug formulation dubbed Emavusertib, which is in phase I/II trials testing its effectiveness in treating myelodysplatic syndromes, acute myeloid leukemia and non-hodgkin lymphomas. It is also developing a new oncology drug candidate, CA-327.

The company, which recently announced its most recent financial results, is focused on strengthening its internal capabilities and growing as a team to enable the delivery of a new class of therapies to its patients. This will be good for its growth and investments, as well as its revenues.

Curis Inc. (CRIS), closed Thursday's trading session at $1.46, off by 0.680272%, on 2,413,057 volume. The average volume for the last 3 months is 2.413M and the stock's 52-week low/high is $1.39/$17.40.

Tempest Therapeutics (TPST)

MarketBeat, InvestorsUnderground and BUYINS.NET reported earlier on Tempest Therapeutics (TPST), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Tempest Therapeutics Inc. (NASDAQ: TPST) (FRA: 3OS) is a clinical-stage oncology firm that is focused on the development of small molecule therapeutics for the treatment of cancer.

The firm has its headquarters in South San Francisco, California. It operates as part of the biotechnology industry, in the healthcare sector. The firm serves consumers around the globe, with a focus on the United States.

The company is party to a collaboration agreement with F. Hoffmann-La Roche Ltd, which involves carrying out a TPST-1120 phase II study, in combination with bevacizumab and atezolizumab in patients with advanced hepatocellular carcinoma. It is focused on immune-mediated and targeted cancer therapies which regulate anti-tumor immunity pathways. The company’s deep and balanced pipeline comprises of best-in-class and first-in-class therapeutics which regulate distinct pathways, helping mount an effective anti-tumor response.

The enterprise’s clinical programs include a selective antagonist of peroxisome proliferator-activated receptor alpha, dubbed TPST-1120, which is undergoing phase I trials evaluating its effectiveness in treating solid tumors; and a dual antagonist of EP4 and EP2, receptors of prostaglandin E2, dubbed TPST-1495, which is also undergoing phase I trials testing its efficacy in the treatment of solid tumors. It also develops a cellular enzyme which regulates the innate immune response in tumors, known as TREX-1.

The firm recently released its latest financial results, with its CEO noting that the firm remained focused on diversifying and strengthening its pipeline of new cancer programs with the potential to treat various indications. This will be good for patients suffering from a range of indications as well as the firm’s growth.

Tempest Therapeutics (TPST), closed Thursday's trading session at $3.74, off by 9.8795%, on 59,857 volume. The average volume for the last 3 months is 59,817 and the stock's 52-week low/high is $2.16/$41.00.

Sellas Life Sciences (SLS)

StockMarketWatch, MarketClub Analysis, TradersPro, MarketBeat, TraderPower, QualityStocks, BUYINS.NET, Profitable Trader Authority, Daily Trade Alert, INO Market Report, OTCtipReporter, PCG Advisory, Penny Pick Finders, PoliticsAndMyPortfolio, Trades Of The Day, Schaeffer's, Small Cap Firm, The Online Investor and PennyStockProphet reported earlier on Sellas Life Sciences (SLS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sellas Life Sciences Group Inc. (NASDAQ: SLS) (FRA: RXK3) is a late-stage bio-pharmaceutical firm that is engaged in developing new cancer immunotherapies for cancer indications.

The firm has its headquarters in New York, the United States and was incorporated in 2006, on April 3rd by Angelos M. Stergiou. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the globe, with a focus on the United States.

The company is party to a strategic collaboration with Merck & Co. Inc., which involves the evaluation of its galinpepimut-S candidate when administered in combination with PD1 blocker pembrolizumab in phase I/II clinical trials which have enrolled patients with various cancer indications, including solid tumors and hematologic malignancies.

The enterprise’s product pipeline is made up of a cancer immunotherapeutic agent known as GPS (galinpepimut-S) which targets Wilms tumor 1. This candidate is in phase I/II clinical trials evaluating its efficacy in the treatment of ovarian cancer and phase 3 clinical trials testing its effectiveness in treating acute myeloid leukemia. It also develops a cancer immunotherapy dubbed nelipepimut-S, which targets the human epidermal growth factor receptor 2. The candidate is in phase IIb trials testing its effectiveness in treating early-stage breast cancer.

The firm recently entered into a license agreement with a Shanghai-based company, GenFleet Therapeutics Inc., which involves the development of GFH009. This move opens the firm up to opportunities in China as well as outside China, which will bolster its growth and bring in more investments as well as revenues, helping create value for its shareholders.

Sellas Life Sciences (SLS), closed Thursday's trading session at $3.75, up 0.536193%, on 338,156 volume. The average volume for the last 3 months is 338,156 and the stock's 52-week low/high is $3.57/$15.0789.

Wave Life Sciences (WVE)

MarketBeat, StreetInsider, Streetwise Reports, Schaeffer's, StockMarketWatch, Kiplinger Today, MarketClub Analysis and InvestorPlace reported earlier on Wave Life Sciences (WVE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Wave Life Sciences Ltd (NASDAQ: WVE) (FRA: 1U5) is a clinical-stage genetic medicine firm that is focused on designing, optimizing and producing new stereopure oligonucleotides through its discovery and drug development platform.

The firm has its headquarters in Singapore and was incorporated in 2012, on July 23rd by Takeshi Wada and Gregory L. Verdine. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the globe.

The company develops drugs using its PRISM drug development platform. It is party to collaboration agreements with the University College London, the University of Louisville, IRBM S.p.A, the Grenoble Institute of Neurosciences, the Western Washington University, the University of Massachusetts, the University of Oxford, Takeda Pharmaceutical Company Ltd and Pfizer Inc.

The enterprise’s product pipeline comprises of a discovery stage program dubbed ATXN3 which has been developed to treat spinocerebellar ataxia 3; an Exon 53 molecule known as WVE-N531 developed to treat Duchenne muscular dystrophy; a mutant SNP3 molecule dubbed WVE-003, which has been developed to treat Huntington’s disease; and a C9orf72 molecule known as WVE-004, for the treatment of fronto-temporal dementia and amyotrophic lateral sclerosis. It also has two pre-clinical programs, including retinitis pigmentosa caused by a P23H mutation in the RHO gene and Usher syndrome type 2A, for the treatment of retinal diseases.

The company remains focused on strengthening and diversifying its pipeline and scaling its manufacturing capabilities to support its needs. This will positively influence revenues into the firm as well as bring in more investors.

Wave Life Sciences (WVE), closed Thursday's trading session at $2.5, up 0.806452%, on 413,553 volume. The average volume for the last 3 months is 413,553 and the stock's 52-week low/high is $1.79/$7.55.

The QualityStocks Company Corner

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

Orano SA, a multinational nuclear fuel cycle company, has responded to a request for information made by the U.S. Department of Energy, stating that fixed demand for HALEU high-assay, low-enriched uranium (HALEU) was one of the major obstacles that needed to be overcome in order to achieve sustainable production. The request for information was issued by the energy department late last year. Its objective was to find more input on its plan to establish a new program to assure the material’s availability, which is required for advanced reactor demonstration and commercial deployment. Currently, light water reactors use 3% to 5% enriched uranium fuel; HALEU is enriched between 5% and 20%. The federal government needs to give serious thought to the comments submitted by Orano and other industry actors. This is because there is an urgent need to start processing the uranium mined by local players, including Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR), into forms that can be used to generate energy or for medical applications instead of depending on only foreign suppliers.

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR),based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon‐free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

Energy Fuels Inc. (UUUU), closed Thursday's trading session at $9.79, up 9.6305%, on 6,998,191 volume. The average volume for the last 3 months is 6.886M and the stock's 52-week low/high is $4.32/$11.39.

Recent News

Silo Pharma Inc. (OTCQB: SILO)

The QualityStocks Daily Newsletter would like to spotlight Silo Pharma Inc. (OTCQB: SILO).

Professor Bryan Roth of the University of North Carolina at Chapel Hill says that psychedelic drugs had demonstrated in studies that they had miraculous effects on mental illnesses. Roth also revealed that his research was personal, explaining that his mother suffered from schizophrenia all her life, having had her first episode when he was about five. This, Roth said, has motivated him to learn more about what goes on in the brain. Schizophrenia is a severe mental disorder in which individuals interpret reality in an abnormal way. Patients suffer from delusions, hallucinations and disordered behavior and thinking. Currently, however, psilocybin and LSD are still classified as Schedule I substances under the Controlled Substances Act. Drugs in this classification are illegal and are labeled dangerous. Researchers hope to change this, and the work being done by companies such as Silo Pharma Inc. (OTCQB: SILO) could unlock the benefits of these substances in treating a number of mental health indications. Silo Pharma (OTCQB: SILO) is committed to developing innovative solutions to address various underserved conditions such as post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s, Parkinson’s, and other rare neurological disorders as part of its focus on merging traditional therapeutics with psychedelic research. “Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves,” a recent article reads. Silo Pharma is involved in a sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease; a scientific research agreement with the University of California San Francisco (“UCSF”) leveraging four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation; an exclusive option agreement with the University of Maryland, Baltimore to explore a novel invention generally known as joint-homing peptide and its use in arthritis-inflamed joints; and an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation as well as a prophylactic treatment for stress-induced disorders and PTSD. “In addition to its university partnerships, Silo entered a joint venture agreement with Zylo Therapeutics Inc. (‘ZTI’), focused on the development of ketamine and psilocybin using ZTI’s Z-Pod(TM) technology for the transdermal time-released delivery of therapeutics.” To view the full article, visit: https://ibn.fm/QWO3w

Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry.

Silo is committed to developing innovative solutions to address a variety of underserved conditions. Combining Silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space.

Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves.

Silo recently engaged Donohoe Advisory Associates LLC for consulting and advisory services in connection with the potential uplisting of Silo’s common shares to the Nasdaq Stock Market.

Research

Silo has entered into research agreements and partnerships with multiple leading medical universities.

The company is involved in a sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action. The investigator in the Netherlands is acquiring the substances for the study and will then finalize the documentation to submit to the ethics committee.

Additionally, in June 2021, Silo announced its entry into a scientific research agreement with the University of California San Francisco (UCSF). The agreement will leverage four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF.

Silo also recently extended its exclusive option agreement with the University of Maryland, Baltimore (UMB) to explore a novel invention generally known as joint-homing peptides. These peptides are being developed for use in the investigation and treatment of arthritogenic processes and can be used for enhanced targeting of therapeutic agents.

This agreement includes the study of two separate peptides. The first is an option and study for the treatment of arthritis. The second is a patented licensed peptide for the central nervous system, with an initial study for MS autoimmune diseases, in addition to rheumatoid arthritis. Animal studies are underway for both initial indications relating to the UMB agreement, with the potential for studies evaluating additional indications in the future.

Finally, Silo signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD. Both candidates are currently being tested in mice and have already provided early data.

In addition to its university partnerships, Silo entered a joint venture agreement with Zylo Therapeutics Inc. (“ZTI”) focused on the development of ketamine and psilocybin using ZTI’s Z-Pod™ technology for the transdermal time released delivery of therapeutics. In November 2021, the company announced ZTI’s reception of its first ketamine shipment and initiation of loading ketamine into its Z-Pod technology. In a news release, Eric Weisblum, CEO of Silo, called the development an “important milestone” that will help the company “study the benefits of slow-release transdermal release of Ketamine.”

Market Overview

According to Coherent Market Insights, the fibromyalgia treatment market was valued at $2.78 billion in 2018 and has a projected CAGR of 3.3% over the forecast period 2018 to 2026. Fibromyalgia is a condition that causes pain all over the body, sleep problems, fatigue, and emotional and mental distress.

The global PTSD therapeutics market is expected to reach $10.68 billion by 2026 with a CAGR of 4.5% during the forecast period from 2018 to 2026, according to a report by Credence Research. Growing prevalence of PTSD is the chief factor driving the global treatment market. Increases in events such as wars, combat, and interpersonal violence has been a major contributing factor. Other factors like growing emphasis on rehabilitation initiatives by governments for treating their war veterans has also been facilitating the increase in demand for PTSD therapeutics.

Fortune Business Insights reports the global Parkinson’s disease treatment market is predicted to grow to $8.38 billion by 2026, with a CAGR of 8.1% during the forecast period. Parkinson’s is a neurodegenerative disease of the central nervous system which primarily affects the brain, causing uncontrollable shaking and tremors, difficulties in balance and restricted body movement making it difficult for the person to function or perform a daily routine.

Management Team

Eric Weisblum is CEO and founder of Silo Pharma. He has over 25 years of Wall Street experience, most recently in the biotechnology sector. He has served on the board of Aikido Pharma and was the president of Sableridge Capital. He has a proven track record in licensing therapeutic assets and assisting in their development. He brings to the company nearly 20 years of expertise in structuring and trading financial instruments. He holds a bachelor’s degree from the University of Hartford’s Barney School of Business.

Dr. Kevin Muñoz was appointed to the Silo board of directors in October 2020. He teaches biomedical sciences and medical intervention for the Passaic County Technical Institute. He previously served as Director of Operations at Physical Medicine and Rehabilitation. He began his career with Harlem Health Promotion Center in New York City as a research assistant. He earned a bachelor’s degree from the University of Michigan and a Doctor of Medicine from Xavier University School of Medicine.

Josh Woolley, M.D., Ph.D., is a Scientific Advisor for Silo. He is an associate professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco. He is also a psychiatrist on staff at the San Francisco Veterans Affairs Medical Center. He is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders Laboratory. He received both his M.D. and his Ph.D. in Neuroscience from UCSF, where he completed his psychiatry residency training.

Charles Nemeroff, M.D., Ph.D., is a Scientific Advisor for Silo Pharma. He directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. He was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine. He received his M.D. and Ph.D. in neurobiology from the University of North Carolina School of Medicine.

Silo Pharma Inc. (OTCQB: SILO), closed Thursday's trading session at $0.24175, up 8.8964%, on 108,085 volume. The average volume for the last 3 months is 108,085 and the stock's 52-week low/high is $0.12/$0.39.

Recent News

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF)

The QualityStocks Daily Newsletter would like to spotlight FuelPositive Corp. (NHHHF).

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) recently announced that experienced global agricultural product operations leader Derek Boudreau joined the company as a strategic advisor, responsible for agricultural implementation. Boudreau joins FuelPositive after more than 27 years with John Deere Company. His addition to the team highlights the company’s build-up toward commercialization of its intellectual property (“IP”), with FuelPositive expecting to begin rolling out the prototype of its modular green ammonia production systems in late summer 2022. A recent article quotes FuelPositive CEO and Board Chair Ian Clifford as saying: “[Boudreau’s] vast experience working in sales, management, manufacturing, and distribution with agricultural equipment and internal combustion engines will help ensure FuelPositive makes the best possible decisions related to the broad range of agricultural opportunities presenting themselves to the company every day…. He is starting off reviewing our intellectual property and working with farmers to build our understanding of their practices, preferences and requirements. His knowledge will play a critical role as we determine and maximize the impact our on-site green ammonia production systems will have on farms and in other applications as we grow.” To view the full article, visit https://ibn.fm/xzjp9

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) is a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements. The company is committed to providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications.

FuelPositive is headquartered in Toronto, Canada.

Hydrogen Economy Problems and FuelPositive’s Carbon-Free Technology

The hydrogen economy is currently facing many challenges. Traditional NH3 manufacturing exists on a massive scale, but centralized facilities result in some of the world’s most concentrated CO2 emissions. In total, an estimated 200 million metric tonnes of NH3 are consumed each year, with greater than 80% utilized by the agricultural sector. NH3 is also being positioned as a viable alternative to fossil fuels.

FuelPositive’s flagship carbon-free ammonia technology provides an innovative solution to these environmental concerns. Developed by Dr. Ibrahim Dincer and his team, the company’s platform allows for the in-situ production of NH3 in an entirely sustainable manner, using only water, air and sustainable electricity.

The production of hydrogen is energy intensive, but it is just one variable hindering the growth of the hydrogen economy. Other hurdles include:

  • Storage – The storage of hydrogen by compression or liquification are both cost prohibitive and unsustainable.
  • Distribution – The distribution network for effective hydrogen deployment has yet to be developed, as the extreme high-pressure distribution requirements to transport hydrogen would result in enormous infrastructure costs.
  • End Use – R&D on the transportation-related end use applications for hydrogen is in its infancy, but almost any vehicle on the road today can be easily converted to run on NH3 at a considerably lower cost per mile traveled when compared to traditional fossil fuels.

A key benefit of FuelPositive’s patent-pending, first-of-its-kind carbon-free NH3 technology is its flexibility. The process allows for small, medium or large-scale production of NH3 on location, minimizing or even eliminating the challenges and volatility associated with storage and transportation to end use. As such, with an appropriately sized FuelPositive system and access to renewable energy, the end use applications for the company’s platform are nearly infinite.

Manufacturing Partnership

On May 19, 2021, FuelPositive announced its selection of National Compressed Air Canada Ltd. (“NCA”) to undertake manufacturing of the company’s Phase 2 hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production.

In a news release detailing the partnership, FuelPositive CEO Ian Clifford noted, “This critical milestone for FuelPositive will confirm the broad application potential for our technology and is the backbone of our Carbon-Free Hydrogen-NH3 offering. Partnering with the knowledgeable and experienced team at NCA on this commercialization project will bring our development-stage program to life.”

Global Ammonia Market Outlook

The global ammonia market was valued at $52.71 billion in 2017 and is forecast to reach $81.42 billion by 2025, growing at a CAGR of 5.59%, according to data from Fior Markets (https://ibn.fm/1OfOB).

The agricultural industry consumes more than 80% of global NH3. Smaller percentages can be attributed to the waste, water treatment, refrigerants, antiseptic, textile, mining and pharmaceutical industries.

One of the most polluting industries on the planet consists of conventional agribusinesses. These polluters are responsible for more greenhouse emissions per year than transportation. This is where FuelPositive’s technology is expected to be extremely beneficial.

Management Team

Ian Clifford is Director, CEO and Founder of FuelPositive Corp. He has over 25 years of experience in the fields of technology and marketing and has successfully led the company to global brand recognition through its unique energy solutions. Since 2006, Mr. Clifford has raised over $50 million in equity financing for FuelPositive. He also co-founded digIT Interactive, a full-service internet marketing company serving Fortune 500 clients, which he sold at the peak of the market in 2000.

Greg Gooch serves as a Director and President of FuelPositive. His multifaceted career in the electronics and finance industries has positioned him as a key advisor and funding partner to start-ups and new technology companies for over 40 years. Mr. Gooch has been involved with FuelPositive since its early days and has remained a significant supporter and consultant to the company over the years. He has a bachelor’s from McGill University and an MBA from the University of Western Ontario.

Dr. Ibrahim Dincer is a scientific advisor to FuelPositive and is recognized as a pioneer and international leader in the area of sustainable energy technologies. Along with his team, Dr. Dincer invented the modular carbon-free ammonia (NH3) production technology that FuelPositive is commercializing. His area of specialty covers various topics including ammonia, hydrogen energy and fuel cells; renewable energy systems; energy storage systems and applications; carbon capturing technologies, and integrated and hybrid energy systems He is currently managing an exemplary team of researchers in this commercialization project.

Marek Warunkiewicz is the company’s Communications & Branding Specialist. He brings more than 40 years of entrepreneurial expertise to the FuelPositive team, having held marketing, branding, advertising, project management and graphic design positions with various companies. Mr. Warunkiewicz has successfully created business-to-business marketing and advertising campaigns for a diverse group of clients ranging from high-tech to agriculture. He co-founded digIT Interactive and ZENN Motor Company alongside Ian Clifford.

Luna Clifford is the Director of Communications for FuelPositive. She has over 10 years of experience as a business owner and advisor, helping build and operate several successful start-up enterprises while managing complex stakeholder relationships. Ms. Clifford excels in strategic planning and team building, and she has completed extensive studies in the fields of communications and health care.

FuelPositive Corp. (NHHHF), closed Thursday's trading session at $0.1175, up 1.468%, on 146,161 volume. The average volume for the last 3 months is 146,161 and the stock's 52-week low/high is $0.09/$0.326.

Recent News

Kronos Advanced Technologies Inc. (OTC: KNOS)

The QualityStocks Daily Newsletter would like to spotlight Kronos Advanced Technologies Inc. (OTC: KNOS).

Kronos Advanced Technologies (OTC: KNOS), a revenue-generating product development and production company that has significantly changed the way air is moved, filtered and disinfected, has developed one of the most effective air purifiers available today. With reports showing that indoor air pollution is a risk factor for several of the world’s leading causes of death, including heart disease, pneumonia, stroke, diabetes, lung cancer, and viruses, air purifiers can help remove or reduce pollutants by using a combination of chemicals, physical filters and devices. A recent article reads: “Kronos is making its presence felt in the growing sector with its proprietary, medical-grade technology, which has been tested as the most effective clean-air solution on the market. The Kronos AIR 5G filters particles down to .0146 microns, far beyond the 3 microns of a traditional HEPA filter. And Kronos air purifiers do more than collect air pollutants – using approximately 30,000 volts, the Kronos AIR 5G air purifier destroys 99.99% of all airborne bacteria, mold and virus particles.” To view the full article, visit https://ibn.fm/xwnRw

Kronos Advanced Technologies Inc. (OTC: KNOS) develops and sells a variety of disruptive, advanced, state-of-the-art air filtration and purification systems that fully remove harmful allergens, bacteria, viruses (including the flu), and even gasses from indoor breathing spaces, including healthcare and other settings.

Kronos’ own patented medical-grade technology is tested as the most effective clean air solution on the market. Kronos filters particles down to .0146 micron (.0146μm) – far beyond the 3 microns (0.3μm) of a traditional HEPA filter. Kronos® not only collects but destroys air pollutants. Kronos® AIR 5G® Air Purifiers use about 30,000 volts inside to actively destroy 99.99% of all airborne bacteria, mold, and virus particles.

Kronos® devices operate silently using nanotechnology to remove 100% of pollutants in a 400ft2 room (up to the whole house) and replenishes the room with pure, clean air every 15 minutes. Indoor household air is often four times more polluted than outdoor air, and Kronos air purifiers act like bionic lungs for the home and protect the people in it.

Unlike traditional HEPA systems that collect pollutants on filters which can, over time, grow mold and bacteria, Kronos’ patented technology destroys and eliminates all manner of harmful particles and deposits them on easy-to-clean collecting plates. This reduces the risk of harmful particles in the air and eliminates the need to replace costly HEPA filters every month.

The Kronos® AIR 5G® Air Purifier destroys and eliminates dust, allergens, bacteria, and even viruses. The AIR 5G® has been third party lab tested and confirmed to kill 99.87% of influenza virus in one hour.

The patented system’s five step process starts with a pre-filter screen that filters and collects hair, pet dander, etc. The air is then pulled through emitter wires which create a 30,000-volt electro field that zaps dangerous particulates. In the ionic field, charged particles are destroyed, killing bacteria and pathogens. The particles are then captured on collecting plates, removing dangerous toxins from circulation. The collecting plate is easily cleaned and reused without buying new filters. The catalytic layer is the final step in the purification process, removing odors and keeping the air fresh and pure. The AIR 5G® has Smart Control Auto Mode, which measures and displays the air quality in the room and self-adjusts fan speed based on how dirty the air is in the room. There’s also an AIR 5G® Smart App that displays the real time Air Quality Index and acts as a remote control.

The Kronos® AIR 5G® Air Purifier is offered in three models:

  • Kronos® AIR 5G® X3 air purifier combines powerful patented TPA® technology with a compact form factor up to six times smaller than other air purifiers, with washable and reusable filters.
  • Kronos® AIR 5G® X5 thoroughly wipes out dust, smoke, dander, bacteria, pollen, viruses, odors, germs, and more from the air, delivering the healthiest breathable air possible. It was developed for some of the world’s most polluted areas and is now available for use in the home. It runs completely silently, passing through five stages of purification to guarantee the cleanest possible air in homes or offices.
  • Kronos® AIR 5G® X8 delivers maximum power, more than doubling the capacity and efficiency of the Kronos X5, with CADR speeds of up to 470 CFM – enough to clean a 1,000ft2 room in just 20 minutes.

Kronos also offers the Kronos Car Air Purifier, the most advanced car air purifier with Kronos’ patented TPA® technology, and FitAir, the best personal air purifying solution that brings clean air anywhere by cleaning within 25ft2 of personal space at an airflow rate of 3x per hour.

Market Overview

The global air purifier market was valued at $10.38 billion in 2020 and is expected to reach $21.15 billion by 2027, achieving a CAGR of 10.7% over the forecast period, according to Brandessence Market Research. The market is primarily driven by the increasing concerns about both outdoor and indoor air pollution, coupled with the associated health problems.

Air pollution is one of the most prevalent concerns, due to worsening environmental condition. According to Health Effect Institute, it accounts for 4.9 million to 8.8 million deaths worldwide each year. Furthermore, as most of our time is spent is indoors, indoor air pollution remains a serious concern to individuals, as well as regulatory agencies. Particles like PM 2.5 can enter indoors through a wide range of sources including car engines, fireplaces, and coal- or natural gas and the infiltration of ambient particulates in urban areas. Even in the absence of solid fuels, indoor ventilation can build up PM 2.5 particles to a greater extent than in outdoor environments. Growing demand for portable air purification filters and systems in urban areas, increased advancements to catch key particulates like coronavirus, and increased regulatory measures to ensure safe environments for professionals in the industrial sector remain leading drivers of growth in the air purifier market.

Poor indoor air quality can cause fatigue, headache, and irritation of the eyes, throat, lungs, and nose, which can have a negative impact on worker productivity. Some air contaminants can cause asthma and other respiratory diseases.

Air purifier adoption is increasing rapidly in the U.S. to minimize health issues caused by poor air quality. Strict air quality standards, guidelines, and regulations in the U.S. are expected to have a positive impact on the market. For instance, the New Jersey Indoor Air Quality standard, NJAC 12:100-13 (2007), sets guidelines and standards related to indoor air quality during working hours in public employee-occupied buildings.

Key manufacturers are focusing on acquisitions and mergers to expand their geographical reach and strengthen their position in the market.

Management Team

Michael Rubinov, President and Head of Business Development

A seasoned hi-tech executive with 25 years of global business experience, Mr. Rubinov has served in various positions in sales, marketing, channel development and partner management. He has worked for large and global organizations such as Intel, NICE Systems, and Boeing (Defense and Security), as well as for start-up companies like Dialogic and Remunera International SA. He was appointed President and Head of Business Development of Kronos Advanced Technologies Inc. in February 2020. Mr. Rubinov holds an MBA, an MS Computer Sciences, and a BS Electrical Engineering.

Joseph L. Florence, Chief Operational Officer & CTO

A dynamic skilled leader in all aspects of business formation, evaluation, and execution, Mr. Florence brings a unique combination of Fortune 100 company experience with a lifetime of entrepreneurial experience to the Kronos team. He is a gifted visionary, possessing the unique ability to see future opportunities and make timely strategic adjustments and is naturally gifted at seeing unrecognized risk and overlooked opportunities. Mr. Florence has a proven track record of transforming companies to better align people, processes, and technologies to meet strategic goals and business metrics resulting in increased market share and profitability.

Kronos Advanced Technologies Inc. (OTC: KNOS), closed Thursday's trading session at $0.0169, up 12.6667%, on 54,610 volume. The average volume for the last 3 months is 54,610 and the stock's 52-week low/high is $0.0111/$0.133.

Recent News

GreenBox POS (NASDAQ: GBOX)

The QualityStocks Daily Newsletter would like to spotlight GreenBox POS (NASDAQ: GBOX).

GreenBox (NASDAQ: GBOX), an emerging and rapidly growing fintech company, has announced an acquisition that will bring significant processing volume portfolio in-house. The asset purchase agreement with Sky Financial & Intelligence, will enhance GBOX margins and create additional revenue-generating opportunities for the company. In the transaction, GreenBox purchased a portfolio of merchant accounts for $16 million in cash and 500,000 restricted common shares. According to the announcement, one of the portfolios has been integrated with GreenBox’s technology and ecosystem for more than a year. During that time, the portfolio grew to more than $1 billion in total processing volume and played a key role in GBOX’s success last year. “The acquisition of the substantial Sky portfolios is yet another stride forward for us and accomplishes two very important things,” said GreenBox chair Ben Errez in the press release. “By bringing a large merchant account portfolio in-house, we eliminate the cost previously incurred from commissions and amplify our margin profile. Second, it allows GreenBox to own these customer relationships, securing a considerable portion of our processing volume base with the bonus of being able to offer additional revenue generating solutions. Lastly, Sky’s processing volume played a vital role for us in meeting the fundamental hurdle requirements in our convertible note.” To view the full press release, visit https://ibn.fm/qoDWo

GreenBox POS (NASDAQ: GBOX) is an emerging financial technology company leveraging proprietary security and token technology to build customized payment solutions for business. The company’s mission is to build compliant, cutting-edge blockchain ledger tokenized solutions for the diverse, evolving and dynamic global market.

GreenBox applications enable an end-to-end suite of turnkey financial products which offer improved fraud detection and better handling efficiency of large-scale commercial payment processing volumes for its merchant clients globally. The company’s proprietary blockchain and smart contract token technologies create seamless payment processing using digital encryption keys.

GreenBox is a unified platform providing scalability for businesses to accept payments, transact, send, settle and convert in a single versatile ecosystem. GreenBox operates a private and proprietary blockchain-based payment platform that offers distinct advantages when compared to traditional payment technologies, including greater security and data privacy, as well as enhanced identity theft protection and quick settlement.

As the settlement engine for financial transactions, GreenBox’s blockchain technology is a distributed ledger that uses digitally encrypted keys to verify, secure and record details of each transaction conducted within GreenBox’s private ecosystem. The speed and security of the platform allows GreenBox to log immense volumes of immutable transactional records in real time for Tier-1 partners around the world.

In November 2021, GreenBox announced the closing of a previously announced $100 million convertible note financing. The company plans to use proceeds for acquisitions, a planned stablecoin spin-off, and additional working capital toward the company’s future growth. The initial conversion price equals a more than 80 percent premium to the market price of the company’s common stock on October 29, 2021, and values the enterprise at more than $700 million upon conversion.

Brands & Solutions

The company offers multiple solutions and brands under the GreenBox label. The other brands that are nested under the GreenBox POS label include coyni, ChargeSavvy, QuickCard, Transact Europe [didn’t yet close] and Northeast Merchant Systems. Each of these brands play a large role in allowing GreenBox to accel in customizing payment solutions across different verticals and industries.

Payment Solutions

The GreenBox platform offers blockchain secure, robust payment processing solutions for both individual consumers and businesses. The company combines the power and security of blockchain with bank-level tools necessary to both settle transactions and monitor cash flows. Customers can transfer cryptocurrencies like USDC, Ethereum or Bitcoin from external decentralized crypto wallets to their GreenBox wallets. They can also exchange those tokens from their GreenBox wallets to any supported coin. Customers can easily offload in USDC to a debit card or a multitude of gift cards.

White Label Solutions

The company’s white label platform allows it to partner with firms seeking blockchain-based tools to manage merchant relationships. White label partners can monitor cash flows, as well as run reports on merchant transactions, chargebacks, agent and affiliate commissions and more. Partners can access the platform through their partner portal to manage business relationships with full visibility. The platform’s cutting-edge technology saves partners time and simplifies their payment processing. It ensures compliance with automated Know Your Customer and Know Your Bank services and allows customers to set up automated payouts.

coyni Stablecoin

The company is planning soon to launch its own stablecoin, coyni (CYN). coyni is equivalent to the value of the U.S. dollar on a one-to-one ratio. Stablecoin allows for instantaneous transactions with blockchain security just like other cryptocurrency tokens, but without the price volatility of traditional cryptocurrencies. The CYN token is expected to make possible features like digital dollar accounts, cross border payments, international payment processing and other payment solutions. As a smart contract technology, coyni will offer instant settlement using the GreenBox blockchain ledger in any location and currency – crypto or fiat – all at lower fees and in a tokenized secure ecosystem.

Market Overview

A Mordor Intelligence report put the transaction value of the global digital payments market at $5.44 trillion in 2020 and projects the market to be worth $11.29 trillion by 2026. That represents a CAGR of 11.21 percent during the period of 2021-2026.

The report notes that the global COVID-19 pandemic and its impact on e-commerce is likely to encourage strengthened international cooperation and further development of policies for online purchasing and supply. The report states, “The pandemic has made it clear that e-commerce can be an important tool/solution, especially considering the fact that e-commerce sales can support small and medium businesses that form the backbone for certain economies. This is expected to substantially spur the growth of digital payment methods across various economies.”

According to Mordor, other drivers of the growth trend in digital payments include:

  • Greater convenience, favorable government policies and evolving consumer behavior worldwide
  • Rapid rise in smartphone penetration throughout emerging economies
  • Introduction of mobile wallets across the world
  • Widespread adoption of retail digital payment services across the vast population of China, serving as a kind of test case for other countries

Management Team

Ben Errez, Chairman of the Board of Directors

Ben Errez’s past positions have included positions at large companies like Microsoft and Intel. He has brought this expertise to lead GreenBox into the forefront of the blockchain-based financial software, services, and hardware market.

Mr. Errez was one of the early managers of Microsoft in 1991. From 1991 to 2004, he served as Software Development Lead for the Microsoft International Office Group. He led the International Microsoft Office Components team (Word, Excel, PowerPoint) in design, engineering, development, and successful deployment. He also served as Executive Representative of Microsoft Office and was a founding member of the Microsoft Trustworthy Computing Team both within the company and internationally. Mr. Errez co-authored the first Microsoft Trustworthy Computing Paper on Reliability. At Microsoft, he was responsible for the development of the first Microsoft software translation Software Development Kit (“SDK”) in Hebrew, Arabic, Thai, and Simplified Chinese, as well as the development of the first bidirectional extensions to Rich Text Format (“RTF”) file format and all bidirectional extensions in text converters for Microsoft Office. He also contributed to the development of the international extensions to the Unicode standard to include bidirectional requirements under the World Wide Web Consortium (“W3C”).

In 2004, Mr. Errez transitioned into the world of consulting, where he held the position of Principal Consultant from founding to the present date, through which he advises clients in the South Pacific region with market capitalizations ranging from $50 million to $150 million on commerce, security, reliability, and privacy.

In 2017, immediately before partnering with Fredi Nisan to launch GreenBox, Mr. Errez was asked to take over the Microsoft Alumni Network for the Southern California region as a regional director. Mr. Errez has been a principal of GreenBox since its inception in 2017.

Fredi Nisan, Chief Executive Officer

Fredi Nisan’s career in technology began during his years of service in the Israeli Defense Forces, where he served as IT Manager for all of Israel’s Northern Bases. After serving in the military, Mr. Nisan opened and operated a computer hardware store before becoming the Inventory Operations Manager for Zicon Israel in 2005, a hardware and software producer. At Zicon, he supervised inventory operations, worked on quality controls for motherboards and chips, and educated customers on software and hardware product functionality. Subsequently, Mr. Nisan moved to the United States, where he worked for One Coach in San Diego, California, as a business coach. One Coach specializes in customized growth solutions for small business owners, including the latest strategies for sales, internet marketing, branding, and ROI. Mr. Nisan was consistently ranked as the top salesperson for small business coaching while working with One Coach.

In 2010, Mr. Nisan launched Brava POS, where he served as President until 2015. Brava POS provided point of sale (“POS”) systems for specialty retail companies. Mr. Nisan developed software to provide clients with solutions for issues ranging from inventory management to payroll to processing high volume transactions in the form of a cloud-based POS system. This system had the capability to manage multiple stores with centralized inventory and process sales without an internet connection, and offered a secure login for each employee, as well as including advanced inventory management and reporting, plus powerful functionality for its end users.

In 2016, Mr. Nisan founded Firmness, LLC. Through Firmness, he created “QuickCitizen,” a software program that simplifies the onboarding process for new clients of law firms specializing in immigration issues. The QuickCitizen software significantly reduced law firms onboarding processing time from more than three hours to approximately 15 minutes. Mr. Nisan has been a principal of GreenBox since its August 2017 inception. In January 2018, Firmness sold QuickCitizen to GreenBox.

Jacquline B. Reynolds, Chief Marketing Officer

Jacqueline B. Reynolds is the company’s Chief Marketing Officer. She served most recently as vice president of marketing for Sprouts Farmers Market. She has built her reputation as a world-class global marketer, working with Coca-Cola, McDonald’s, Verizon, Walmart, L’Oréal, Xbox, 7-Eleven and many other Fortune 500 brands. She has managed award-winning marketing programs with partners such as the NFL, Super Bowl LIV, the Olympics, the FIFA World Cup, Sony Pictures, Universal Music and others.

GreenBox POS (NASDAQ: GBOX), closed Thursday's trading session at $4.26, even for the day, on 175,952 volume. The average volume for the last 3 months is 163,048 and the stock's 52-week low/high is $2.24/$20.78.

Recent News

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF)

The QualityStocks Daily Newsletter would like to spotlight EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF).

  • Chase Edgelow and the EverGen Infrastructure team has sought to cater to the rapidly rising demand for carbon-free energy sources through a focus on renewable natural gas (“RNG”)
  • Current forecasts suggest that as much as 10% of North America’s natural gas demand could be satisfied by RNG in the coming future
  • EverGen is planning to expand their production footprint, recently signing a letter of intent to acquire a stake in an agricultural project in Alberta wherein biodegradable waste will be converted into RNG and sold to FortisBC
  • RNG proponents increasingly believe that the fuel source could eventually play a role in targeting two of society’s most pressing issues – the world’s growing waste production as well as its mission to achieve a carbon neutral future

The world produces over 2.12 billion tons of waste per annum; To put that figure into perspective, if all the waste was put on trucks, it would circle around the world 24 times (https://ibn.fm/UJnsY). For Chase Edgelow, that is an opportunity. The CEO and Founder of British Columbia-based EverGen Infrastructure (TSX.V: EVGN) (OTCQB: EVGIF) is creating a cutting edge renewable energy company, focused around converting organic waste into renewable natural gas (“RNG”), a non-fossil fuel form of natural gas. With governments the world over pledging to pursue a carbon neutral future in the coming years, RNG stands to play a significant role in the decarbonization of North America’s gas supply going forward. Forecasts suggest that as much as 10% of the continent’s natural gas demand could be satisfied by RNG in the not-too-distant future. Nowhere is that phenomenon more evident than within the utilities sector. 

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF) is developing Canada’s Renewable Natural Gas Infrastructure Platform, starting on the west coast in British Columbia. The company is combating climate change and helping communities contribute to a sustainable future by acquiring, developing, building, owning and operating a portfolio of renewable natural gas (RNG), waste-to-energy, and related infrastructure projects.

While EverGen is currently focused on British Columbia, its continued growth is expected across other regions of North America. RNG is produced differently than conventional natural gas, without drilling wells. RNG is derived from biogas, which is captured from decomposing organic waste in landfills, food waste, agricultural waste matter and wastewater from treatment facilities. This waste feedstock is supplied to an anaerobic digester which contains bacteria that breaks down organic matter in the absence of oxygen. The resulting biogas is captured and cleaned to create carbon neutral or carbon negative RNG to be used by the existing North American gas pipeline grid. By capturing these emissions and transforming them into RNG, then combusting into CO2, the overall greenhouse gases (GHG) impact is materially less potent than allowing natural decomposition to release methane into the atmosphere. Liquid and solid digestate matter is a byproduct of the RNG production process and is used as fertilizer and in other applications.

EverGen operates three projects in British Columbia. The company was incorporated in 2020 and went public in 2021, with its common shares listed on the TSX Venture Exchange under ticker symbol ‘EVGN’. In February 2022, EverGen’s common shares began trading on the OTCQB Venture Market in the U.S. under ticker symbol ‘EVGIF’. The company is headquartered in Vancouver.

Portfolio Projects

Fraser Valley Biogas is one of three projects in EverGen’s portfolio. Located in Abbotsford, British Columbia, the facility has been digesting manure and off-farm organics since 2011 and was the first agricultural digester in Canada to produce RNG. The RNG generated through this project is part of a FortisBC program to supply renewable gas to homes, businesses and other customers. Fraser Valley Biogas also provides Abbotsford farms with renewable fertilizer via the digestate produced. EverGen acquired Fraser Valley Biogas early in 2021 and is currently enhancing and expanding the facility. These optimization projects resulted in record production during the month of September 2021, supporting the growing demand for RNG in British Columbia. Optimization activities contributed an additional 18% of RNG production for September and a 9% higher year-to-date production compared to the previous year. The facility produces approximately 80,000 gigajoules of RNG, enough to heat more than 1,000 homes for a year.

Net Zero Waste Abbotsford, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and RNG expansion project. The British Columbia Utilities Commission recently approved a 20-year offtake agreement between the facility and FortisBC, an electricity and gas utility. Under this agreement, FortisBC will purchase up to 173,000 gigajoules of RNG annually for injection into its natural gas system upon completion of an anaerobic digester project at Net Zero Waste Abbotsford. Once construction is complete, this project is expected to produce enough energy to meet the needs of more than 1,900 homes.

Sea to Sky Soils, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and potential future RNG expansion project which has been operating near Pemberton, British Columbia, on Lil’wat Nation land since 2012. The Lil’wat Nation is a key partner and supporter of the facility, which has employed a majority of its staff from the First Nation since inception. The Sea to Sky Soils facility processed approximately 160 percent of its forecast tonnage in the second half of 2021. In total, Sea to Sky Soils processed approximately 36,000 tons of organic waste in 2021. The facility is working with the Ministry of Environment to expand its operational capacity in 2022. EverGen has partnered with local municipalities – including Metro Vancouver and the municipality of Pemberton – for the delivery of additional organic waste to the facility. The facility is an important part of EverGen’s RNG infrastructure platform and serves as a source of valuable feedstock to support the company’s existing and future operations.

Market Outlook

A report from Global Market Insights states that the biogas market is projected to see significant growth over the next few years, driven by a shifting preference to utilize biogas to reduce emission levels from traditional fuels. Escalating RNG usage by gas utilities as a sustainable and low carbon alternative to supply heat and electricity in industries and buildings will further stimulate growth. RNG is increasingly deployed across the transport sector, especially for heavy vehicles and vessels, to abate GHG emissions.

Many North American gas utilities have set RNG targets of 5% to 15% of production by volume in 2030, compared to less than 1% by volume in 2020. FortisBC has a goal of including 15% RNG in its gas supply by 2030. EverGen believes this presents a potential C$16 billion+ opportunity for RNG producers.

Management Team

Chase Edgelow is co-founder and CEO at EverGen. He has over 15 years of specialized private investment, finance, and technical expertise in the energy and infrastructure sectors. His background is as a Facilities Engineer with Petro-Canada, independently managing energy infrastructure capital projects located in western Canada. He holds a Professional Engineer designation from the province of Alberta.

Mischa Zajtmann is co-founder and President at Evergen. He has 15 years of experience providing consulting and management for Canadian and American companies in the natural resources and energy space. He is a corporate securities lawyer who began his career at Blake, Cassels & Graydon LLP. His J.D. is from the University of Saskatchewan Law School. He’s a member of the British Columbia Bar.

Sean Mezei is COO at EverGen. He has 20 years of experience in the RNG industry, having served previously as the president of Greenlane Biogas and as a senior manager at QuestAir, and founder and president of Dekany Consulting. He was a co-chairman of the American Biogas Council’s RNG working group for six years. He has been a Registered Professional Engineer in the province of British Columbia since 1994.

Natasha Monk is CFO at EverGen. She is a CPA with 12 years accounting, financial reporting, and tax experience in public practice and industry. She is currently a partner at Affirm LLP, where she advises and consults to a wide variety of companies in multiple industries across public and private sectors. Prior to joining EverGen, she worked at KPMG. She graduated from the University of Calgary.

EverGen Infrastructure Corp. (OTCQB: EVGIF), closed Thursday's trading session at $3.87, even for the day, on  volume. The average volume for the last 3 months is 1,600 and the stock's 52-week low/high is $2.78/$4.21.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

Last week, the U.S. House of Representatives approved a measure that would legalize cannabis across the country as well as eliminate criminal penalties for any individual who possessed, distributed or manufactured the substance. Legislators passed the Marijuana Opportunity Reinvestment and Expungement (MORE) Act in a 220 to 204 vote. The same act was approved in the House in 2021 but failed to advance in the Senate. This measure, which was sponsored by House Judiciary Chairman Jerrold Nadler, will deschedule marijuana from the government’s Schedule I classification under the Controlled Substances Act. It will also set up procedures for the expungement of prior convictions from individuals’ records and levy a tax on the sale of marijuana products. This tax will start at 5%, before eventually increasing to 8%. Should marijuana prohibition be ended at the federal level, entities such as Advanced Container Technologies Inc. (OTC: ACTX) will grow a lot faster because of the wider market that will be opened.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.

Products

Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.

Containers

ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Thursday's trading session at $1, even for the day, on 261 volume. The average volume for the last 3 months is 261 and the stock's 52-week low/high is $0.66/$5.00.

Recent News

AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF)

The QualityStocks Daily Newsletter would like to spotlight AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF).

Researchers have found evidence that the human immune system is more prone to inflammation after an individual suffers from a mild case of the coronavirus. Inflammation occurs as an individual’s body responds to infection from germs. However, in some coronavirus-infection cases, the immune response causes damage throughout an individual’s body. The study was carried out by researchers at the Karolinska Institute in Sweden, as well as Germany’s Technical University of Munich and the Helmholtz Center Munich. Given that systemic inflammation can trigger more serious health complications, there is an urgent need to develop new therapies to manage this type of inflammation. Companies such as AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) are focused on bringing to market the next generation of remedies to inflammation, and these could help lots of patients in need.

AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) is a fully integrated, publicly traded, early-stage life science enterprise dedicated to delivering therapeutic interventions to public health through discovery, innovation and successful collaborations in the life science industry. The company’s leadership drives discovery programs for clinical complexities presented by malnutrition, viral infectious diseases and the inflammatory response system.

AREV’s business model leverages the core competency of producing proprietary compounds through its innovative extraction methodologies, scientific advisory board (SAB), experienced staff, and executive leadership to drive its product pipeline. AREV’s strategy is to generate revenue from selling its branded products via its online technology platform, Medicine Merchant™, an enterprise marketing platform built to enable consumers to have access to novel therapeutic approaches to human nutrition, endemic diseases, and neglected chronic related co-morbidities. The company also expects to generate revenue from toll processing and government procurement of its products that address malnutrition and related health issues.

AREV is focused on innovations in biomedicine and maintains a significant footprint in clinical human nutrition utilizing proprietary protein blends and terpenes, complimented with vitamins and minerals. The company has utilized its expertise to design and deliver innovation in therapeutic interventions using its exclusive botanical, fungi and marine compounds to address medical conditions driven by presenting global epidemiological characteristics of multiple challenges to international human and animal health. AREV uses its proprietary extractions allowing characterizations from botanical and marine sources in therapeutic foods and medicines that comprise its development pipeline.

Development of AREV’s pipeline is fostered by collaborations with academic centers, clinical research organizations and government institutions committed to facilitating discovery of promising new clinical approaches presented in peer reviewed journals. AREV operates under the guidance of its SAB and a growing number of strategic collaborations with CROs and academic research centers, including the Linus Pauling Institute at Oregon State University.

AREV is a member of both BIOTECanada and The Biotechnology Industry Organization (BIO):

  • BIOTECanada is the national industry association with over 200 members located nationwide, reflecting the diverse nature of Canada’s health, industrial and agricultural biotechnology sectors.
  • BIO is the world’s largest advocacy association representing member companies, state biotechnology groups, academic and research institutions, and related organizations across the United States and 30+ countries.

Products

AREV’s end-product and target categories include therapeutic interventions, botanical drugs, ready-to-use therapeutic food (RUTF), enteral nutrition formulas and early-stage small molecule antiviral therapeutics demonstrating novel mechanisms of action.

Wright and Well Branded Line

Wright and Well Branded Line is the company’s branded line of therapeutic cannabinoid and terpene-based formulations. The topical line includes solutions for burns, wounds, skin disorders and muscle relief, as well as a lubricant for intimacy. The oral line addresses inflammation, heart health, high blood pressure and viral infections. These products are currently produced at CBD99, a licensed processor in Sandy, Oregon. The company also has a strategic relationship with a Canadian licensed hemp and cannabis processor in Vancouver, British Columbia.

SUS-TAINN™

The company’s products in the RUTF category are branded under SUS-TAINN™ (Superior Utility Supplementation Therapeutic Agent for Indicated Nutritional Needs). SUS-TAINN™ is the flagship line of products stemming from AREV’s collaboration with Voynich Biosciences.

RUTFs like SUS-TAINN™ are the cornerstone to international famine response and currently represent more than 20 percent of public health commodity procurement spending. SUS-TAINN™ is purchased by agencies ranging from the U.S. Department of State AID for International Development to the World Food Program and is distributed by an increasingly substantial number of non-governmental organizations.

RESTORE™

The company’s enteral nutrition product is branded as RESTORE™. For patients experiencing caloric compromise, enteral nutrition, a liquid form of nourishment, is often required. RESTORE™, the initial enteral formulation from AREV, is based on organic plant nutrition for patient populations who have demonstrated overt clinical need for rational enhanced caloric intake and micronutrient supplementation.

RESTORE™ provides a proprietary blend of high-quality proteins, antioxidants, minerals and proven anabolic agents, combined with pre- and probiotics. The company plans to submit for Medicaid formulary inclusion and reimbursement designations in various jurisdictions characterized by the Ryan White CARE Act during the second half of 2022.

REV-I1™

REV-I1™ is the company’s small molecule drug discovery model for phytomedicinalization, based on advanced computational characterization and next generation affinity selection that affords new opportunities in HIV antiretroviral research. REV inhibition offers a critical approach to inhibiting HIV replication and addressing viremia in highly conserved sanctuary regions.

Phytomedicinal therapeutic discovery and development offer clinically viable approaches to a wide range of scientific challenges that currently elude successful contemporary interventions. A cornucopia of diverse validated compounds allows AREV to explore a distinguished range of promising approaches that are in stages of pre-clinical validation. Combining AREV’s versatile extraction capability with highly sensitive analytical techniques (LC-MS, MS-MS) is expected to allow new medicinal chemistry to be identified and characterized, leading to therapeutic candidates in the company’s commercial drug discovery platform.

Market Overview

A report from Verified Market Research valued the global plant protein market at $29.4 billion in 2020 and forecast that it could surpass $162 billion by 2030, which would make up 7.7% of the global protein market, according to a report released in August by Bloomberg Intelligence.

The RUTF market was valued at $363.72 million in 2019 and is projected to reach $807.89 million by 2027, growing at a CAGR of 10.5% for the forecast period. The market is primarily driven by the efforts of governments and non-governmental organizations to reduce the rate of severe acute malnutrition. Moreover, changing trends and growing developments related to diet-related deficiencies, as well as increasing incidences of famine and disasters, are likely to fuel the growth of the RUTF market in the near future, according to the report.

Management Team

Michael Withrow is the founder, chairman and CEO of AREV. He is a successful natural products and technology entrepreneur with more than 25 years of experience. He has started and sold companies and has worked with companies such as CAVA Health Care (formerly Alternative Extracts Inc.), North American BioExtracts Inc., and Canadian Pacific Phytoplankton Ltd. He has also served as president and CEO of a specialty cannabis technology company.

Kevin Phelps, CPA, is a director at AREV. He is CEO and president of Immune Therapeutics Inc., a bio-pharmaceutical company. He began his career with Price Waterhouse before joining Eastman Kodak Company as part of an executive team that successfully spun out the Bio Products Division into Genencor International Inc., an international industrial bio-chemicals company. He later joined Trillium Group, a regional private equity firm, as a partner, where he served on behalf of the firm as CFO of Vaccinex Inc., a vaccine development company, and chairman of AccuMed Inc., a medical device company. He has served as Chairman of Oyagen, a biotech that over the past decade has developed drug discovery methods that have enabled it to explore vulnerabilities in HIV, Ebola and coronaviruses.

Denby Greenslade is corporate secretary and interim CFO at AREV. She has served as corporate secretary and director for several companies in the mining, biotech and IT industries and has more than 15 years of corporate secretarial, corporate governance, and securities regulation experience. She graduated from Simon Fraser University with a Bachelor of Arts in Communication.

Allan Echino is a director at AREV. He was a founder and director of Corlac Resources, an oil producer, and Calroc Industries, an oil service company based in Alberta. Mr. Echino arranged funding for a licensed producer in the cannabis sector and quickly learned the business and health benefits of cannabis and mushrooms.

Mel Maxwell is a director at AREV. During his 40-plus year career, he has founded six companies. His degrees in business and computer science initially took his career toward IT ventures that entailed software development, IT consulting, e-commerce solutions, real estate development, pathogen remediation solutions and wholesale vehicle aggregation. He finds continued enjoyment in consulting with other businesses and entrepreneurs.

Scientific Advisory Board

Roscoe M. Moore, Jr., DVM, MPH, PhD, a former United States Assistant Surgeon General, provides strategic planning for AREV’s nutritional and drug discovery platforms as chairman of the company’s scientific advisory board. Dr. Moore is a member of the board of advisers of the Institute of Human Virology (IHV) and the board of directors of the Global Virus Network associated with IHV, University of Maryland Medical Center. IHV is the first research institute in the U.S. to link basic science, population studies, and clinical trials in an effort to develop new vaccines and treatments; its 80 faculty members contribute to research on pandemic pathogens, ranging from COVID-19 to HIV.

Dr. Moore served with the United States Department of Health and Human Services (HHS) and was responsible, for the last 12 years of his career, for global development support within the Office of the Secretary, HHS, with primary emphasis on implementing innovations in essential health care commodity procurement programs for resource-challenged countries. Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service, entering with the U.S. National Institutes of Health (NIH) and rising to the rank of Rear Admiral. Dr. Moore worked at the Center for Veterinary Medicine, U.S. Food and Drug Administration (FDA), before becoming senior epidemiologist within the National Institute for Occupational Safety and Health of the U.S. Centers for Disease Control and Prevention (CDC), where he also served as an epidemic intelligence service officer.

Robert Melamede, PhD, received his doctorate in molecular genetics and biochemistry from the University of the City of New York Graduate Center, focusing on base excision repair of free radical damages in DNA. For decades, he led laboratory efforts in a world-class, federally funded lab, where he discovered endonuclease VIII. Dr. Melamede did a sabbatical at the Scripps Institute and subsequently established an in vitro monoclonal antibody facility at the University of Vermont, developing antibodies to free radical damages in DNA and to DNA repair enzymes. Working with a collaborator, Dr. Melamede worked on metabolism and cancer cells as a professor and chair of the biology department at the University of Colorado at Colorado Springs. He co-founded Cannabis Science Inc., a public company, retiring as the company’s chief executive in 2014. Dr. Melamede continues his innovative research in the private sector.

Harold Smith, PhD, is the founder, CEO, and president of Oyagen Inc., a biotechnology company developing therapeutics for various disease states, including HIV and cancer. Dr. Smith is also a tenured professor of biochemistry and biophysics at the University of Rochester, School of Dentistry and Medicine, with additional appointments as a professor in genetics and pathology and as a member of the Center for RNA Biology.

Richard Van Breemen, PhD, is a Professor of Medicinal Chemistry in the Department of Pharmaceutical Sciences of the College of Pharmacy at Oregon State University. His research interests include cancer prevention by dietary antioxidants and prostate cancer prevention by the carotenoid lycopene, mass spectrometry-based pharmacological screening of natural products and combinatorial libraries for drug discovery, and high throughput screening to assess drug metabolism, toxicity and bioavailability. Dr. Van Breemen made The Analytical Scientist’s Power List in 2020 and 2021. His work in biomedical mass spectrometry earned him an initial spot, and he clocked in the Top 100 analytical scientists from around the world on the Power List in 2021.

Dr. Blake Hawley is the founder & CEO of Motega Health Inc. Dr. Hawley has worked in animal health, pharma and food across 23 countries and four continents. He holds an MBA from KU and his doctorate in veterinary medicine and zoology degrees from NC State. He serves on multiple non-profit advisory boards, including the KU MBA Advisory Board. Dr. Hawley is a 2017 graduate of Pipeline Entrepreneurs and a graduate of the Village Capital Agricultural 2016 Entrepreneur Cohort.

Dr. Hawley previously served as the General Manager of Australasia; Regional General Manager of Russia and Central Eastern Europe (consisting of 22 countries); and Managing Director of the United Kingdom and Ireland for Hill’s Pet Nutrition, a division of Colgate-Palmolive. His experience includes 10 years of profit and loss responsibilities in these territories, with consistent double-digit annual revenue growth in each of the 10 years. He oversaw products competing in the arthritis, dermatology, obesity, gastrointestinal, urinary, and cancer markets, among others. Dr. Hawley also has background in e-commerce, data analytics, and social media and most recently served as Worldwide Director of Global Digital for Hill’s Pet Nutrition.

Uma Dhanabalan, MD, MPH, FAAFP, MRO, CMS, advises AREV on product development and formulation. She is the founder and CEO of Global Health & Hygiene Solutions LLC, whose mission is to promote wellness and prevent illness locally and globally and runs an independent practice at Uplifting Health & Wellness in Cambridge, Massachusetts. Dr. Dhanabalan, a fellow of the American Academy of Family Physicians, graduated from UMDNJ, Newark, New Jersey, with her medical degree and trained in family medicine at MUSC in Charleston, South Carolina; she earned her master’s degree in public health from Harvard’s School of Public Health in Boston, Massachusetts, and continued her training at Harvard in occupational and environmental medicine.

Special IP Advisor

Douglas Sorroco practices in all areas of intellectual property law including patent, trademark, copyright, technology, and e-commerce and assists clients with intellectual property matters requiring litigation, licensing, technology counselling and complex transactions.

Mr. Sorroco is ranked in Band 1 (the top band) for intellectual property law by the highly regarded Chambers USA: America’s Leading Lawyers for Business 2021, and he was selected for inclusion in The Best Lawyers in America® 2022 for Litigation – Intellectual Property, Litigation – Patent, Patent Law and Technology Law. In 2021, Best Lawyers named him the Oklahoma Lawyer of the Year for Technology Law. In 2021, Managing Intellectual Property continued to rank Doug as an IP Star. Mr. Sorroco was selected for inclusion in Oklahoma Super Lawyers 2021 and was also selected by attorney peers for inclusion in Oklahoma Super Lawyers – Rising Stars Edition (2010).

AREV Life Sciences Global Corp. (OTC: AREVF), closed Thursday's trading session at $0.177, even for the day, on  volume. The average volume for the last 3 months is 420 and the stock's 52-week low/high is $0.0655/$0.32616.

Recent News

Nowigence Inc.

The QualityStocks Daily Newsletter would like to spotlight Nowigence Inc.

Nowigence has introduced Pluaris, an all-in-one, easy-to-use personal knowledge management platform designed to assist users with automated reading and analysis of textual data. “The system reads and analyzes articles, documents and other textual data, enabling readers to learn more in less time, uncover hidden insights, and stay on top of the information they need to know. Pluaris helps individuals, teams and entire enterprises make sense of massive amounts of textual data, converting them into bite-size nuggets of intelligence in a short span of time,” a recent article explains. “Once Pluaris has done its job, users simply scan their customized newsfeeds to see summaries and extracted intelligence for each item uploaded. They can also view graphical analysis of the annotations and analyzed content for unbiased importance ranking. In addition, Pluaris assists in drilling down to any level of granularity using filters. Thanks to Pluaris, users discover new connections, topics and insights.” To view the full article, visit https://ibn.fm/dteue

Nowigence Inc. is a fast-growing SaaS (Software-as-a-Service) company that develops and sells a ready-to-use artificial intelligence (AI) platform called Pluaris™ that automates reading and analysis of textual data. Individuals, teams, and enterprises can now quickly distill knowledge buried in narrative-intensive documents instantaneously from various data sources, both public and private.

Pluaris is created for those who want to read more in less time. It is a Personal Knowledge Management (PKM) tool that generates an annotated data feed based on your topics of interest and automatically creates a permanent personal knowledge base from your feed and private uploads. It has human-like capabilities for comprehending textual data. It summarizes, provides precise answers to questions asked, analyzes different data perspectives, discovers new connections, creates organized nested notes, and allows teams to work collaboratively by sharing in real-time from anywhere in the world to draw informed conclusions.

By integrating state-of-the-art data processing techniques in an intuitive interface at an affordable subscription price, Nowigence puts the power of data science in the hands of consumers. It helps individuals, teams, and organizations to quickly build expertise on one or multiple topics by generating a trove of critical information.

Nowigence targets two user types that rely heavily on fast and accurate research as primary adopters of the Pluaris platform. The first is knowledge workers of all kinds – anyone whose job is to “think for a living” like marketing professionals, researchers, legal professionals, academics, journalists, editors, scientists, and other professionals. The second are individual users who are life-long learners, hobbyists, and enthusiasts of all stripes.

Rather than spending time reading information to gain knowledge from one source at a time, users of Pluaris can gain knowledge from hundreds or thousands of sources in seconds. Keyword-based search-and-retrieval applications don’t open documents, nor read their content, nor extract key points, conduct cause and effect analysis or answer questions specifically. Pluaris includes all those features and goes one step further, with its semantic capabilities to empower users with interpretations of retrieved information. Nowigence estimates this feature alone can save typical researchers between one and three hours per workday. The platform also reduces “noise” by extracting only important and relevant information on every topic being monitored or researched. This helps cut down on information overload, a major source of workplace stress.

Pluaris Builds Intelligence

The Problem

In the modern world, virtually everyone needs to consume a tremendous amount of text-based information, in both our personal and professional lives, but doing so is exceptionally challenging because of:

  • Information Overload: For virtually any significant topic of interest, the amount of textual information available and continually generated is vastly more than can be consumed by an individual.
  • Pervasive Distractions: Thanks to modern technology, we are constantly bombarded with new inputs (e-mails, instant messages, social media, and more) reducing our attention span, leading all too often to TL;DR (Too Long, Didn’t Read).
  • Highly Imperfect Human Recall: The information that we do find time to read is easily forgotten. Even if we retain some of the key insights, the details are almost certainly lost.

Even when working in teams, we often end up researching the same content as our colleagues, and too much of the information acquired by one individual is lost in translation with the communication process to others.

Pluaris

Nowigence has worked with stalwarts and pioneers in the fields of Machine Learning (ML) and Natural Language Processing (NLP) from its early days. The company was keen to solve the big problem of the information age – too much data exists and cannot be processed manually.

Pluaris is designed to be used by regular people from day one with no need for extensive training. The platform is used across different functions and sectors, adapting to clients’ ever-changing needs. Its state-of-the-art no code editing gives organizations the flexibility to improve and tailor their results without hiring data scientists, and real time information retrieval ensures the client never misses any piece of intelligence.

Pluaris adapts to the unique needs by which individuals absorb knowledge. It doesn’t impose structured or rigid methodology. Real time operation means that Pluaris will deliver outputs instantaneously with a click.

A Nowigence team of experts spent three years training Pluaris to understand the context of every sentence it reads. If Pluaris does make an error in contextual interpretation, the user can correct it, which will instantly give the correction precedence over the ML’s algorithmic outputs. This takes away the biggest criticism against AI/ML platforms, that annotating (labeling) data and developing training datasets to build models takes too much time and effort from internal teams.

Use Cases

I need to stay on top of the latest news for my industry. Pluaris automatically retrieves and analyzes news on your topics of interest every day, so you can quickly scroll through an annotated news feed on your phone, tablet or laptop, while finishing your morning coffee.

Example: A Pluaris enterprise customer was interested in tracking news and events in the telecom industry. Nowigence was able to quickly create and then fine-tune a list of topics to monitor. In less than a week, they had an annotated news feed covering the telecom industry available to their team.

I have to come up to speed on a new topic as quickly as possible. Upload a few related websites and documents to Pluaris and within minutes you are exploring this new area of interest, scanning the summaries, gaining new insights about this topic, and finding new keywords to broaden your search and deepen your understanding.

Example: A customer who was already using Pluaris for business intelligence decided to use his account to make improvements in his health after he received a report from his doctor of a high fasting blood sugar level.

  • He uploaded a few research reports to Pluaris, read through the summaries, and explored the annotated labels. Based on that analysis, he set up Pluaris to monitor topics such as “lowering fasting blood sugar” and “low glycemic food.”
  • From those results, he built an action list of daily habits for diet and fitness and, within a couple months, brought his fasting blood sugar level back down.

I want to be able to access the information I’ve read in the past and synthesize it with my current understanding. As you continue to add more and more information to the system over time, Pluaris never forgets. You are building a knowledge base of the information that is most relevant to you.

Example: A Pluaris user at one of the world’s largest aluminum mining companies was tasked with preparing talking points for her manager for an upcoming investor meeting. Over time using Pluaris, she had built a database of documents, including transcripts, notes, Q&A sessions, speeches, annual reports, and internal documents, some of which were from previous investor meetings. She was able to quickly explore that database through the Pluaris Dashboard and using various filters. She then pulled this information together in a Pluaris Notebook and shared that note directly with her boss.

Market Outlook

Pluaris users include:

  • Knowledge WorkersGartner estimates there are more than 1 billion worldwide as of December 2019.
  • Students in Higher Education: ICEF estimates there are 250 million worldwide as of 2020. This is Nowigence’s initial target group from a market penetration perspective.
  • Personal/Home Use: Statista estimates there are 4.7 billion active internet users worldwide as of January 2021.

Nowigence offers tiered pricing, starting at $10/month/user for individuals, while team and enterprise users, who have access to more features to facilitate collaboration and integrations to other enterprise tools, start at $45/month/user.

As a result, the Total Available Market (TAM) is more than a billion users and over $1 trillion. The Market Opportunity (the Serviceable Obtainable Market or SOM) for Nowigence is $11 billion in the combined PKM and Cognitive Computing space defined by Pluaris.

This market is growing rapidly too. The Cognitive Computing market alone was valued at $8.87 billion in 2018 and is projected to reach a value of $87.39 billion by 2026, growing at a CAGR of 31.6% from 2019 to 2026, according to Allied Market Research.

Nowigence offers differentiated value compared to other Personal Knowledge Management (PKM) tools, which have reached as many as 250 million users (Evernote) and have shown rapid adoption (Roam Research reached 60,000 users and $1 million ARR within 6 weeks of launching paid plans). Unlike Pluaris, these tools do not automatically monitor public or private sources to add to your knowledge base, nor do they provide summaries or extract intelligence. Pluaris differs from search engines as well, in that search engines do not access or store personal knowledge, and they also do not summarize or extract intelligence.

Management Team

Anoop Bhatia is the founder and CEO of Nowigence Inc., where he has worked full-time since 2015. Previously, he worked as a global operation strategic transformation leader for Momentive Performance Material (formerly GE Silicones). He has worked for over two decades in various General Electric companies across different countries, including the U.S., India, The Netherlands and Germany. He played a key role in establishing GE Silicones as the first-ever wholly owned foreign subsidiary established in India in 1996. He received his Bachelor of Engineering in Chemical Engineering from BITS in India and did his post-graduate studies in management from Heriot-Watt at Edinburgh in Scotland.

Gordon Haupt is the Chief Technology Officer at Nowigence. He has more than 20 years of experience building and leading diverse engineering and operations teams, and a strong technical background in machine learning, signal processing, and statistical data analysis, including applications in speech and text, biotechnology, and computer vision. He is a named inventor on 15 issued patents and is experienced in all phases of engineering development and operations. He holds a B.S. degree in Engineering Mechanics from the University of Wisconsin and M.S. and Ph.D. degrees from Stanford University in Aeronautics and Astronautics.

David Evans is the company’s acting CFO & General Counsel. As an attorney and licensed CPA in the state of New York, he has extensive experience in multistate and international tax policies and guidelines, federal taxation laws, mergers and acquisitions, including valuation of closely held businesses. He is a contributing author to the New York State Tax Service, a six-volume publication of NYS tax laws and regulations. His prior experience includes being a Managing Director for UHY Advisors LLC, a board member and chairperson of the Tax Division Executive Committee of New York State Society of Certified Public Accountants and a past president of the Estate Planning Council of Eastern New York. He holds degrees from Hofstra University and State University of New York at Buffalo.


Recent News

chart

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS (“SaaS”) platform, has announced that the Sequire Cannabis & Psychedelic Conference is scheduled for April 20, 2022, from 9 a.m. to 4 p.m. ET. The conference will be held via SRAX’s Sequire Virtual Events. The one-day virtual event is expected to draw significant numbers; almost 9 million active small cap investors have been invited to attend. The event agenda keynote addresses by several well-known names in the industry and also includes some 25 cannabis and psychedelic companies offering 25-minute presentations. “This our second annual Sequire Cannabis & Psychedelic Conference,” said SRAX vice president of community and events Morgan Fogg in the press release. “We are delighted by the public companies joining the program this year and have some stimulating speakers rounding out our keynotes and panels. We recently launched new 1:1 feature updates to the Sequire Virtual Events platform, so we are looking forward to having our audience experience that too.” To register for the event, visit https://ibn.fm/3MkzE. To view the full press release, visit https://ibn.fm/twwLx

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Thursday's trading session at $4.13, off by 4.6189%, on 66,666 volume. The average volume for the last 3 months is 66,661 and the stock's 52-week low/high is $3.53/$7.29.

Recent News

Cepton Inc. (NASDAQ: CPTN)

The QualityStocks Daily Newsletter would like to spotlight Cepton Inc. (NASDAQ: CPTN).

  • Cepton continues to be at forefront of state-of-the-art engineering science; sponsors The AutoDrive Challenge(TM) II and serves as an exclusive LiDAR supplier
  • During this competition, faculty members and students from ten North American universities will spend four years developing autonomous vehicles that require no human interaction in their operations
  • Participating teams will work with directional lidars for the first time as academic community recognizes Cepton lidars for their exceptional combination of performance, reliability, and embeddability

As a leading innovator in the LiDAR space, Cepton (NASDAQ: CPTN) has always been committed to becoming the bridge between cutting-edge science and the automotive industry. Autonomous driving and its great enabler – LiDAR technology – are ready to take over mobility space, as the innovative technology makes strides in terms of decreasing costs and improving commercialization potential. Cepton appears determined to be a visible part of that landscape, as it becomes a sponsor and an exclusive LiDAR provider for ten universities in North America gathered in a four-year STEM education program called The AutoDrive Challenge(TM) II (https://ibn.fm/283iq).

Cepton Inc. (NASDAQ: CPTN) is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

  • Reliability – The durable design uses common, easily attainable materials.
  • Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
  • Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
  • Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s recent merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Cepton Inc. (NASDAQ: CPTN), closed Thursday's trading session at $3.45, off by 6.7568%, on 336,309 volume. The average volume for the last 3 months is 336,042 and the stock's 52-week low/high is $3.44/$80.16.

Recent News

Hollywall Entertainment Inc. (OTC: HWAL)

The QualityStocks Daily Newsletter would like to spotlight Hollywall Entertainment Inc. (OTC: HWAL).

  • Hollywall Entertainment Inc. currently has a market cap of $73.53 million, attributed mainly to its leveraging of developing technologies
  • The company, through HW Vision, a wholly-owned subsidiary, is pushing 5G and banking on its adoption over the coming years, projected to drive a 52% growth in the 5G services market by 2030
  • Hollywall is also exploring new ways to create digital equity as it seeks to address the digital divide
  • Through its investment in 5G, Big Data, and AI, Hollywall is not only growing its digital marketplace presence but also driving value for its shareholders

Hollywall Entertainment (OTC: HWAL) has positioned itself as a telecommunication, media, infrastructure, technology, broadcasting, and entertainment company. Through its budding list of subsidiaries, the company has achieved a market cap of $73.53 million as of March 2022. For a company founded in 2009, its growth has been incredible and has been primarily attributed to its identification and capturing of high-growth technologies (https://ibn.fm/v7PkQ).

Hollywall Entertainment Inc. (OTC: HWAL) is a telecommunication, media, technology, broadcasting and entertainment company. Through various subsidiaries, Hollywall maximizes rights to its music, film, television, software and game libraries. Hollywall owns exclusive and nonexclusive rights to market, manufacture and distribute music master recordings performed by multiple platinum-selling acts.

Hollywall was founded in 2009. The company currently has two corporate offices – one in Washington D.C. and the other in New York City.

Hollywall Entertainment Inc. (Hollywall) Subsidiaries

Hollywall has a portfolio of operating subsidiaries spanning various industries, including infrastructure development, 5G and telecommunications, broadcasting, education, media and entertainment.

Hollywall is a minority majority-controlled consortium enterprise company led by founder and President/CEO Darnell Sutton, a highly recognized visionary and award-winning business and social leader.

HWAL continues to expand its business enterprise to numerous city and state municipalities and government agencies throughout the country, including: Washington DC, New York, Virginia, Massachusetts, Pennsylvania, Texas and California, as well as within the Blackbelt regions of Alabama, Louisiana, Mississippi, Georgia and North Carolina, leading the way in developing and implementing solutions to work toward closing the broadband digital divide that has been forced upon the most vulnerable in underserved urban and rural communities nationwide.

Hollywall Development Company (“HWDC”)

HWDC builds, restores and creates “smart” cities/communities and fiber networks throughout the U.S. HWDC services, initiatives and investments include broadband and 5G networks, IOT, smart city technologies, energy, tele-medicine, tele-education, transportation, clean water, waste management and the development of green environments.

HWDC employment growth opportunities continue to attract the industry’s best, brightest and most seasoned corporate executives to join its staff, as well as its ongoing efforts to develop highly effective and profitable strategic partnerships with investment banks, global capital funds, public financial and wealth management firms, construction and engineering companies, telecommunications companies, federal agencies, state and local governments, nonprofits, faith-based organizations and housing authorities.

HWDC’s Smart Cities division aims to provide various services and solutions, such as fiber-optic networking, data centers, smart kiosks, charging stations, security and camera systems, smart traffic monitoring, emergency alert systems, gunshot detection, backup power solutions, smart connected buildings, connected and autonomous vehicles, intelligent transportation systems, advertising and more.

HW Vision and Omnipoint Technology Inc.

Hollywall Entertainment advanced its technological footprint by acquiring top United States telecommunications firm Omnipoint Technology Inc. in 2020. Through the formation of a new wholly owned subsidiary, HW Vision, Hollywall intends to offer state-of-the-art services in the continuously growing digital marketplace, such as:

  • 5G and Fiber Network installation services
  • Affordable high-speed internet access
  • Telehealth services
  • Domain hosting
  • Web conferencing
  • Managed internet services
  • Nationwide unlimited talk, text and data cellphone plans
  • Video broadcasting

In conjunction with its Omnipoint Technology partner, HW Vision has created and developed unique branding for streaming media programming, live television and on-demand content. Offerings from the HW Vision brand are expected to be available for purchase early in 2021.

Hollywall Entertainment Digital Music Network and Hollywall TV

The Hollywall Entertainment Digital Music Network (“HW Network”) has been constructed to sell single song downloads, artist album downloads and ringtones, as well as licensing music for commercial use. Hollywall Music is an owner of legacy music and video collector sets that are distributed to retail, wholesale and download or streaming services. This music library has been protected for over 20 years, and it contains some of the rarest and most coveted unpublished records by legends in the music industry.

Market Outlook

Covering various industries that are continuously expanding, such as telecommunications, media, technology, construction, infrastructure, entertainment and broadcasting, Hollywall is uniquely positioned to secure a prominent role and leverage continued growth opportunities for its subsidiaries.

The 5G sector alone could generate significant interest and market opportunities for Hollywall via HWDC and its community-focused initiatives, including the development of smart cities. The global 5G market was estimated at $41.48 billion for 2020 and is expected to reach an impressive $414.5 billion by 2027, expanding at a CAGR of 43.9% (https://ibn.fm/mgXIu).

Management Team

Darnell Sutton is the Founder, CEO and Chairman of Hollywall Entertainment Inc. Mr. Sutton has over 40 years’ experience with many talents and vast experience as a veteran in the music recording industry, publishing, distribution, live entertainment, television, broadcasting, film and sports athlete, TV/film celebrity and artist management.

Darnell Sutton has represented and worked with some of the greatest athletes and entertainers of our time, including the “King of Pop” Michael Jackson, former heavyweight boxing champion Mike Tyson, current Welterweight Boxing Champion Floyd Mayweather, tennis superstar Serena Williams, Julius “Dr. J” Erving and incomparable multiple Grammy award-winning performers such as The Jacksons, Patti Labelle, Roberta Flack, MC Hammer, Dionne Warwick and Mariah Carey… just to name a few.

“Darnell Sutton, is one of the most exciting master communicators, creative developers and innovators of our time”…says, Tom Stein, Success Magazine.

“After many years of developing, producing and acquiring some of the world’s finest entertainment properties, we are honored to present Hollywall Entertainment companies to the marketplace. We are thrilled to join forces and work with some of the most brilliant and talented Hollywood and Wall Street executives, who have a combined shared experience of industry-recognized excellence,” Sutton said in a news release.

Roxanna Green is the Chief of Staff for Hollywall Entertainment Inc. She has over 30 years of diverse background experience ranging from corporate management to finance. Her experience includes providing corporate legal and financial guidance to both public and private companies, as well as spearheading audits, merger and acquisition negotiations, branding, marketing and public relations initiatives. She has spent the majority of her 30 years in the entertainment and media industry. She has worked with diverse institutions such as banks and securities firms, among others.

Hollywall Entertainment Inc. (OTC: HWAL), closed Thursday's trading session at $0.9699, off by 0.975037%, on 1,431 volume. The average volume for the last 3 months is 1,431 and the stock's 52-week low/high is $0.33/$2.90.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.